Rivermark Medical, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Rivermark Medical, Inc. - overview
Established
2021
Location
Milwaukee, WI, US
Primary Industry
Medical Devices & Equipment
About
Established in 2021 and based in Wisconsin, US, Rivermark Medical, Inc. is a healthcare company that provides minimally invasive device therapy for treating benign prostatic hyperplasia. The company was founded by its CEO, Adam Kadlec, and Andy Doraiswamy. In October 2024, Rivermark Medical, Inc.
raised USD 30 million in Series C funding led by American Century Investments, View Ventures, Cadence Healthcare Ventures, and Anduril Ventures GmbH. Rivermark Medical develops medical devices for the treatment of benign prostatic hyperplasia (BPH), which is a condition often affecting older men that causes an enlarged prostate gland, leading to urinary issues. The company’s product line includes the FloStent System, which is a device designed to treat BPH by restoring normal urinary function. The FloStent System is inserted into the urethra during a minimally invasive procedure.
The company plans to utilize the October 2024 funding raised to advance its clinical development and commercialization of the FloStent System for treating benign prostatic hyperplasia.
Current Investors
Venture Investors, Time BioVentures, View Ventures
Primary Industry
Medical Devices & Equipment
Sub Industries
Surgical Devices, Diagnostic Equipment
Website
www.rivermarkmedical.com
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.